ACQUIRED HEMOPHILIA A

被引：20

作者：

Franchini, Massimo ^{[1
]}

Lippi, Giuseppe ^{[2
]}

机构：

[1] Univ Hosp Parma, Dept Pathol & Lab Med, Immunohematol & Transfus Ctr, Parma, Italy

[2] Univ Hosp Parma, Clin Chem Lab, Dept Pathol & Lab Med, Parma, Italy

来源：

ADVANCES IN CLINICAL CHEMISTRY, VOL 54 | 2011年 / 54卷

关键词：

FACTOR-VIII; ANTIBODIES; RITUXIMAB; INACTIVATION; INHIBITORS; PROGNOSIS; DIAGNOSIS; KINETICS; BINDING; IGG;

D O I：

10.1016/B978-0-12-387025-4.00003-0

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Acquired hemophilia A is a rare but often life-threatening hemorrhagic disorder characterized by an autoantibody directed against coagulation factor VIII. Fifty per cent of cases are idiopathic whereas the remaining 50% are associated with pregnancy, autoimmune conditions, malignancies and drugs. In this review the actual knowledge on diagnostic and therapeutic aspects of this disease will be summarized.

引用

页码：71 / 80

页数：10

共 50 条

[41] Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study
Dobbelstein, Christiane
Moschovakis, Georgios Leandros
Tiede, Andreas
ANNALS OF HEMATOLOGY, 2020, 99 (09) : 2105 - 2112
[42] Diagnosis, laboratory aspects and management of acquired hemophilia A
Toschi, Vincenzo
Baudo, Francesco
INTERNAL AND EMERGENCY MEDICINE, 2010, 5 (04) : 325 - 333
[43] Acquired Hemophilia A: An Update on the Etiopathogenesis, Diagnosis, and Treatment
Zanon, Ezio
DIAGNOSTICS, 2023, 13 (03)
[44] Acquired hemophilia A with sigmoid colon cancer: successful treatment with rituximab followed by sigmoidectomy
Ichikawa, Satoshi
Kohata, Katsura
Okitsu, Yoko
Suzuki, Makiko
Nakajima, Shinji
Yamada, Minami F.
Onishi, Yasushi
Yamamoto, Joji
Suzuki, Sozo
Ishizawa, Kenichi
Kameoka, Junichi
Harigae, Hideo
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 90 (01) : 33 - 36
[45] Acquired Hemophilia A: Retrospective Analysis of 49 Cases From a Single Chinese Hemophilia Center
Yang, Yanhui
Xue, Feng
Shi, Hao
Wang, Hongmei
Zhang, Lei
Ji, Linxiang
Yang, Renchi
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2015, 21 (01) : 35 - 40
[46] Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen
Simon, Barbara
Cegledi, Andrea
Dolgos, Janos
Farkas, Peter
Gaddh, Manila
Hanko, Laszlo
Horvath, Robert
Kaposi, Ambrus
Magyar, Laszlone
Masszi, Tamas
Szederjesi, Attila
Wohner, Nikolett
Bodo, Imre
BLOOD, 2022, 140 (18) : 1983 - 1992
[47] Rituximab in the treatment of acquired hemophilia
Stachnik, Joan M.
ANNALS OF PHARMACOTHERAPY, 2006, 40 (06) : 1151 - 1157
[48] Acquired Hemophilia A: A Retrospective Multicenter Analysis of 42 Patients
Liu, Yanhui
Ruan, Xiang
Lei, Pingchong
Shang, Baojun
Zhu, Zunmin
Chen, Shengmei
Wang, Dao
Wang, Ruijuan
Li, Xiqing
Xue, Fei
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2023, 29
[49] Acquired hemophilia A: A concise review
Franchini, M
Gandini, G
Di Paolantonio, T
Mariani, G
AMERICAN JOURNAL OF HEMATOLOGY, 2005, 80 (01) : 55 - 63
[50] Acquired hemophilia A: Updated review of evidence and treatment guidance
Kruse-Jarres, Rebecca
Kempton, Christine L.
Baudo, Francesco
Collins, Peter W.
Knoebl, Paul
Leissinger, Cindy A.
Tiede, Andreas
Kessler, Craig M.
AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (07) : 695 - 705

← 1 2 3 4 5 →